Full-dose blood thinner treatments can reduce the need for vital organ support such as ventilation in moderately ill patients hospitalized for COVID-19, according to interim results from a clinical trial announced today by the National Institutes of Health.

The patients were not in intensive care or on organ support when enrolled in the study, which found full doses of heparin were safe and better at reducing the need for ventilation or other organ support than the lower doses normally given to prevent blood clots in hospitalized patients.

The findings complement an earlier study that found routine use of full-dose blood thinners does not benefit COVID-19 patients when started in the intensive care unit. The investigators are working to make the full study results available as soon as possible, NIH said.

Related News Articles

Headline
The Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee today recommended the approval of Johnson & Johnson’s COVID-…
Headline
The Substance Abuse and Mental Health Services Administration will host a March 3 roundtable discussion on the academic, social and emotional impacts of…
Headline
Due to the COVID-19 public health emergency, the Centers for Medicare & Medicaid Services will apply an automatic extreme and uncontrollable circumstances…
Headline
Israeli patients aged 70 and older were much less likely to require mechanical ventilation for COVID-19 after most people in their age group had received the…
Headline
AHA today released a one-stop web hub for hospitals and health systems to find communication resources related to COVID-19 vaccines. The hub pulls…
Headline
The Food and Drug Administration will allow undiluted frozen vials of the Pfizer COVID-19 vaccine to be transported and stored at conventional pharmaceutical…